TVARDI THERAPEUTICS INC (TVRD) Stock Price, Forecast & Analysis
USA - NASDAQ:TVRD - US1407553072 - Common Stock
TVRD Key Statistics, Chart & Performance
The current stock price of TVRD is 4.19 USD. In the past month the price decreased by -37.37%.
TVRD Latest News, Press Relases and Analysis
TVRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 43.96 | 914.89B | ||
| JNJ | JOHNSON & JOHNSON | 18.15 | 453.76B | ||
| MRK | MERCK & CO. INC. | 9.85 | 216.68B | ||
| PFE | PFIZER INC | 7.62 | 138.67B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.2 | 96.19B | ||
| ZTS | ZOETIS INC | 18.89 | 53.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.48B | ||
| VTRS | VIATRIS INC | 4.36 | 11.86B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.2 | 11.06B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.78 | 7.95B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.88B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.71 | 4.10B |
Related stock screener links
About TVRD
Company Profile
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Company Info
TVARDI THERAPEUTICS INC
3 Sugar Creek Ctr Blvd, Ste 525
Sugar Land TEXAS US
Employees: 10
Phone: 17134898654
TVARDI THERAPEUTICS INC / TVRD FAQ
What does TVRD do?
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Can you provide the latest stock price for TVARDI THERAPEUTICS INC?
The current stock price of TVRD is 4.19 USD. The price increased by 4.23% in the last trading session.
Does TVARDI THERAPEUTICS INC pay dividends?
TVRD does not pay a dividend.
What is the ChartMill technical and fundamental rating of TVRD stock?
TVRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is TVARDI THERAPEUTICS INC (TVRD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TVRD.
Can you provide the market cap for TVARDI THERAPEUTICS INC?
TVARDI THERAPEUTICS INC (TVRD) has a market capitalization of 39.30M USD. This makes TVRD a Nano Cap stock.
Can you provide the short interest for TVRD stock?
The outstanding short interest for TVARDI THERAPEUTICS INC (TVRD) is 22.06% of its float.
TVRD Technical Analysis
TVRD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TVRD. While TVRD seems to be doing ok healthwise, there are quite some concerns on its profitability.
TVRD Financial Highlights
Over the last trailing twelve months TVRD reported a non-GAAP Earnings per Share(EPS) of -78.48. The EPS decreased by -37.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVRD Forecast & Estimates
14 analysts have analysed TVRD and the average price target is 20.11 USD. This implies a price increase of 379.92% is expected in the next year compared to the current price of 4.19.
For the next year, analysts expect an EPS growth of 98.33% and a revenue growth -82.49% for TVRD